BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hepatocellular Carcinoma readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Hepatocellular Carcin
 oma\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07081633-1959@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07081633)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Durval
 umab and Tremelimumab With Lenvatinib as First-line Treatment in Patients 
 With Unresectable Hepatocellular Carcinoma\nEstimated primary completion: 
 30 November 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dur
 valumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07081633
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07081633-2015@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT07081633)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Durv
 alumab and Tremelimumab With Lenvatinib as First-line Treatment in Patient
 s With Unresectable Hepatocellular Carcinoma\nEstimated primary completion
 : 30 November 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/t
 remelimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07081633
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06984718-1994@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT06984718)
DESCRIPTION:Cadonilimab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Pha
 se II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Sec
 ond-line HCC\nEstimated primary completion: 30 November 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06984718
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06538935-2014@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Apatinib: Phase 2 readout est. (NCT06538935)
DESCRIPTION:Apatinib\, phase 2\, Hepatocellular Carcinoma.\nStudy: SBRT Com
 bined With Adbelimumab and Apatinib for Perioperative and Conversion Thera
 py of Hepatocellular Carcinoma\nEstimated primary completion: December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06538935
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04912765-1974@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04912765)
DESCRIPTION:Nivolumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Neoanti
 gen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From 
 CRC\nEstimated primary completion: December 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT04912765
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06454578-2014@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Apatinib: Phase 2 readout est. (NCT06454578)
DESCRIPTION:Apatinib\, phase 2\, Hepatocellular Carcinoma.\nStudy: Adjuvant
  Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recur
 rence After Curative Resection\nEstimated primary completion: December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06454578
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04344158-1993@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Penpulimab: Phase 3 readout est. (NCT04344158)
DESCRIPTION:Penpulimab\, phase 3\, Hepatocellular Carcinoma.\nStudy: A Phas
 e III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochlor
 ide Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Car
 cinoma (HCC)\nEstimated primary completion: December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/penpulimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04344158
URL:https://assetmemo.bio/drug/penpulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07192185-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07192185)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Syst
 emic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients
  With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab\nEst
 imated primary completion: 1 December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07192185
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07192185-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07192185)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Syste
 mic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients 
 With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab\nEsti
 mated primary completion: 1 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07192185
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03419481-1973@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03419481)
DESCRIPTION:Pembrolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Pem
 brolizumab in Hepatocellular Carcinoma\nEstimated primary completion: 30 D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrol
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT03419481
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03259867-1974@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03259867)
DESCRIPTION:Nivolumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Combina
 tion of TATE and PD-1 Inhibitor in Liver Cancer\nEstimated primary complet
 ion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT03259867
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06031285-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06031285)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Perio
 perative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Pati
 ents With PVTT: A Phase-2 Clinical Trial\nEstimated primary completion: 30
  December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevac
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06031285
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05062837-1972@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Camrelizumab: Phase 2/3 readout est. (NCT05062837)
DESCRIPTION:Camrelizumab\, phase 2/3\, Hepatocellular Carcinoma.\nStudy: He
 patectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC\n
 Estimated primary completion: 30 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05062837
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05062837-2014@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Apatinib: Phase 2/3 readout est. (NCT05062837)
DESCRIPTION:Apatinib\, phase 2/3\, Hepatocellular Carcinoma.\nStudy: Hepate
 ctomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC\nEsti
 mated primary completion: 30 December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/apatinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05062837
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03937830-1959@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT03937830)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Combin
 ed Treatment of Durvalumab\, Bevacizumab\, Tremelimumab and Transarterial 
 Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Bili
 ary Tract Carcinoma\nEstimated primary completion: 31 December 2026. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT03937830
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03937830-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT03937830)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Combi
 ned Treatment of Durvalumab\, Bevacizumab\, Tremelimumab and Transarterial
  Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Bil
 iary Tract Carcinoma\nEstimated primary completion: 31 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT03937830
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03937830-2015@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT03937830)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Comb
 ined Treatment of Durvalumab\, Bevacizumab\, Tremelimumab and Transarteria
 l Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Bi
 liary Tract Carcinoma\nEstimated primary completion: 31 December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/tremelimumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT03937830
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07243951-1994@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT07243951)
DESCRIPTION:Cadonilimab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Phase
  II Clinical Study on the Efficacy and Safety of the Combination of Cadoni
 limab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Car
 cinoma and Intrahepatic Cholangiocarcinoma\nEstimated primary completion: 
 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cad
 onilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07243951
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05844046-1959@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05844046)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Sequen
 tial or Up-front Triple Treatment With Durvalumab\, Tremelimumab and Bevac
 izumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients\nEstimat
 ed primary completion: 31 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05844046
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06698250-1959@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06698250)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Zanzal
 intinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatoce
 llular Carcinoma (ZENOBIA)\nEstimated primary completion: 31 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06698250
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05257590-1974@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05257590)
DESCRIPTION:Nivolumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: CVM-111
 8 in Combination With Nivolumab for Unresectable Advanced Hepatocellular C
 arcinoma\nEstimated primary completion: 31 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05257590
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05844046-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05844046)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Seque
 ntial or Up-front Triple Treatment With Durvalumab\, Tremelimumab and Beva
 cizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients\nEstima
 ted primary completion: 31 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05844046
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05844046-2015@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT05844046)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Sequ
 ential or Up-front Triple Treatment With Durvalumab\, Tremelimumab and Bev
 acizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/tremelimumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05844046
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06698250-2015@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT06698250)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Zanz
 alintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepato
 cellular Carcinoma (ZENOBIA)\nEstimated primary completion: 31 December 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/tremelimumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06698250
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04134559-1973@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04134559)
DESCRIPTION:Pembrolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Che
 ckpoint Inhibition In Pediatric Hepatocellular Carcinoma\nEstimated primar
 y completion: 1 January 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04134559
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04472767-1974@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04472767)
DESCRIPTION:Nivolumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Cabozan
 tinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatoc
 ellular Carcinoma\nEstimated primary completion: 31 January 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04472767
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04472767-2009@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT04472767)
DESCRIPTION:Ipilimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Caboza
 ntinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepato
 cellular Carcinoma\nEstimated primary completion: 31 January 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04472767
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04472767-2031@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT04472767)
DESCRIPTION:Cabozantinib\, phase 2\, Hepatocellular Carcinoma.\nStudy: Cabo
 zantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepa
 tocellular Carcinoma\nEstimated primary completion: 31 January 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/cabozantinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT04472767
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05377034-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270215
DTEND;VALUE=DATE:20270216
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05377034)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Mult
 inational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resi
 n Microspheres) Followed by Atezolizumab Plus Bevacizumab\, vs SIRT (SIRT-
 Y90) Followed by Placebo in Locally Advanced HCC Patients\nEstimated prima
 ry completion: 15 February 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05377034
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05377034-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270215
DTEND;VALUE=DATE:20270216
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05377034)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Multi
 national Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin
  Microspheres) Followed by Atezolizumab Plus Bevacizumab\, vs SIRT (SIRT-Y
 90) Followed by Placebo in Locally Advanced HCC Patients\nEstimated primar
 y completion: 15 February 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05377034
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06400160-1973@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06400160)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Clinical Trial of TB511 in Advanced Solid Tumors\nEstimated primary compl
 etion: March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pe
 mbrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06400160
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05516628-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05516628)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Deep
 \, Multi-omics Phenotyping to Predict Response\, Resistance and Recurrence
  to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carc
 inoma\nEstimated primary completion: March 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05516628
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07246668-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07246668)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Ph
 ase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Ca
 rbon Ion Radiotherapy With Atezolizumab and Bevacizumab Combination Therap
 y in Patients With Advanced Hepatocellular Carcinoma\nEstimated primary co
 mpletion: March 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07246668
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05516628-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05516628)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Deep\
 , Multi-omics Phenotyping to Predict Response\, Resistance and Recurrence 
 to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carci
 noma\nEstimated primary completion: March 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05516628
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07246668-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07246668)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Pha
 se II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Car
 bon Ion Radiotherapy With Atezolizumab and Bevacizumab Combination Therapy
  in Patients With Advanced Hepatocellular Carcinoma\nEstimated primary com
 pletion: March 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07246668
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07422753-2009@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07422753)
DESCRIPTION:Ipilimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Pros
 pective\, Randomized Study of TACE Combined With Sintilimab\, Bevacizumab\
 , and Ipilimumab N01 Treating Advanced HCC\nEstimated primary completion: 
 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipilimuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 422753
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06427941-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06427941)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase 1/2 Study of BGB-B2033\, Alone or in Combination With Tislelizumab 
 With or Without Bevacizumab\, in Participants With Advanced or Metastatic 
 Solid Tumors\nEstimated primary completion: 31 March 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06427941
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06427941-2390@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:BGB-B2033: Phase 1/2 readout est. (NCT06427941)
DESCRIPTION:BGB-B2033\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase 1/2 Study of BGB-B2033\, Alone or in Combination With Tislelizumab Wi
 th or Without Bevacizumab\, in Participants With Advanced or Metastatic So
 lid Tumors\nEstimated primary completion: 31 March 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/bgb-b2033#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06427941
URL:https://assetmemo.bio/drug/bgb-b2033#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06360042-1972@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT06360042)
DESCRIPTION:Camrelizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Anti
 -PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment f
 or Unresectable HCC\nEstimated primary completion: 31 March 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/camrelizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06360042
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06360042-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06360042)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Anti-
 PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment fo
 r Unresectable HCC\nEstimated primary completion: 31 March 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06360042
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06360042-2014@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Apatinib: Phase 2 readout est. (NCT06360042)
DESCRIPTION:Apatinib\, phase 2\, Hepatocellular Carcinoma.\nStudy: Anti-PD-
 1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for U
 nresectable HCC\nEstimated primary completion: 31 March 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06360042
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07175441-1959@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07175441)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Evalua
 tion of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Partic
 ipants With Advanced Unresectable Hepatocellular Carcinoma\nEstimated prim
 ary completion: April 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07175441
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07560488-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07560488)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Ipili
 mumab N01 Combined With Sintilimab\, Bevacizumab Biosimilar\, and Hepatic 
 Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Inte
 rmediate-Advanced Hepatocellular Carcinoma\nEstimated primary completion: 
 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7560488
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07560488-2009@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07560488)
DESCRIPTION:Ipilimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Ipilim
 umab N01 Combined With Sintilimab\, Bevacizumab Biosimilar\, and Hepatic A
 rterial Infusion Chemotherapy as Conversion Therapy for Unresectable Inter
 mediate-Advanced Hepatocellular Carcinoma\nEstimated primary completion: A
 pril 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075
 60488
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07175441-2015@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT07175441)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Eval
 uation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Part
 icipants With Advanced Unresectable Hepatocellular Carcinoma\nEstimated pr
 imary completion: April 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tremelimumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07175441
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06995105-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06995105)
DESCRIPTION:Bevacizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Per
 sonalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcin
 oma\nEstimated primary completion: 1 April 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06995105
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06397222-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06397222)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Sinti
 limab Plus Bevacizumab and SIRT for Intermediate-advanced HCC\nEstimated p
 rimary completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06397222
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06986785-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06986785)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Stu
 dy of BL-B01D1 Monotherapy\, BL-B01D1 in Combination With Lenvatinib\, BL-
 B01D1 in Combination With PD-1 Monoclonal Antibody\, and BL-B01D1 in Combi
 nation With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Adva
 nced Hepatocellular Carcinoma\nEstimated primary completion: May 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06986785
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05451043-1959@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05451043)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Durval
 umab and Tremelimumab in Combination With Propranolol and Chemotherapy for
  Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)\nEstimated pr
 imary completion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05451043
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05451043-2015@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT05451043)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Durv
 alumab and Tremelimumab in Combination With Propranolol and Chemotherapy f
 or Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)\nEstimated 
 primary completion: 1 May 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tremelimumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05451043
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06265285-1974@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06265285)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Compa
 rison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab
  Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls 
 (CCBW) Program\nEstimated primary completion: 1 May 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06265285
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05738616-1972@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Camrelizumab: Phase 3 readout est. (NCT05738616)
DESCRIPTION:Camrelizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: Lenv
 atinib Combined With TACE and Camrelizumab in Conversion Resection for Adv
 anced Hepatocellular Carcinoma (LEN-TAC Study)\nEstimated primary completi
 on: 1 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/camre
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05738616
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07052253-1994@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270510
DTEND;VALUE=DATE:20270511
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT07052253)
DESCRIPTION:Cadonilimab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Pha
 se II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet fo
 r Advanced HCC.\nEstimated primary completion: 10 May 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07052253
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07919717-1974@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270512
DTEND;VALUE=DATE:20270513
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07919717)
DESCRIPTION:Nivolumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: NIVO+IP
 I Neoadjuvant Therapy for Recurrent Resectable HCC\nEstimated primary comp
 letion: 12 May 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07919717
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07919717-2009@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270512
DTEND;VALUE=DATE:20270513
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07919717)
DESCRIPTION:Ipilimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: NIVO+I
 PI Neoadjuvant Therapy for Recurrent Resectable HCC\nEstimated primary com
 pletion: 12 May 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07919717
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05440708-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270525
DTEND;VALUE=DATE:20270526
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT05440708)
DESCRIPTION:Atezolizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: A 
 Study of TTI-101 as Monotherapy and in Combination in Participants With Lo
 cally Advanced or Metastatic\, and Unresectable Hepatocellular Carcinoma\n
 Estimated primary completion: 25 May 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05440708
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05440708-1973@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270525
DTEND;VALUE=DATE:20270526
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05440708)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: A
  Study of TTI-101 as Monotherapy and in Combination in Participants With L
 ocally Advanced or Metastatic\, and Unresectable Hepatocellular Carcinoma\
 nEstimated primary completion: 25 May 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05440708
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05440708-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270525
DTEND;VALUE=DATE:20270526
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT05440708)
DESCRIPTION:Bevacizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: A S
 tudy of TTI-101 as Monotherapy and in Combination in Participants With Loc
 ally Advanced or Metastatic\, and Unresectable Hepatocellular Carcinoma\nE
 stimated primary completion: 25 May 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05440708
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04721132-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04721132)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Atez
 olizumab and Bevacizumab Before Surgery for the Treatment of Resectable Li
 ver Cancer\nEstimated primary completion: 31 May 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT04721132
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04721132-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT04721132)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Atezo
 lizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liv
 er Cancer\nEstimated primary completion: 31 May 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT04721132
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05063565-1959@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05063565)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: TheraS
 phere With Durvalumab and Tremelimumab for HCC\nEstimated primary completi
 on: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durval
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05063565
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05063565-2015@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT05063565)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Ther
 aSphere With Durvalumab and Tremelimumab for HCC\nEstimated primary comple
 tion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trem
 elimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05063565
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07192848-2014@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Apatinib: Phase 2 readout est. (NCT07192848)
DESCRIPTION:Apatinib\, phase 2\, Hepatocellular Carcinoma.\nStudy: Adebreli
 mab + Apatinib in Advanced HCC Post-Systemic Therapy\nEstimated primary co
 mpletion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 apatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07192848
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07412054-1973@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07412054)
DESCRIPTION:Pembrolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Len
 vatinib and Pembrolizumab With or Without BCAA in Unresectable HCC\nEstima
 ted primary completion: 1 June 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07412054
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07870772-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07870772)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Lenva
 tinib Plus Bevacizumab and PD-1 Inhibition Versus Bevacizumab Plus PD-1 In
 hibition After Progression on Bevacizumab Plus Sintilimab in Unresectable 
 Hepatocellular Carcinoma: A Prospective\, Randomized\, Two-Cohort\, Phase 
 II Study\nEstimated primary completion: 30 June 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07870772
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07682272-2014@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Apatinib: Phase 2 readout est. (NCT07682272)
DESCRIPTION:Apatinib\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Trial 
 of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatm
 ent of Resectable Hepatocellular Carcinoma\nEstimated primary completion: 
 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/apatinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07682
 272
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04803994-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT04803994)
DESCRIPTION:Atezolizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: The 
 ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoemboli
 zation (TACE) in Intermediate-stage HepatoCellular Carcinoma\nEstimated pr
 imary completion: July 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04803994
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04803994-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT04803994)
DESCRIPTION:Bevacizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: The A
 BC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoemboliz
 ation (TACE) in Intermediate-stage HepatoCellular Carcinoma\nEstimated pri
 mary completion: July 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04803994
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07075419-1993@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Penpulimab: Phase 1/2 readout est. (NCT07075419)
DESCRIPTION:Penpulimab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: JDB1
 53 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Tr
 eatment Failure\nEstimated primary completion: 1 July 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/penpulimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07075419
URL:https://assetmemo.bio/drug/penpulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06205706-1973@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270714
DTEND;VALUE=DATE:20270715
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06205706)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  BI-1910 as a Single Agent and in Combination With Pembrolizumab for the T
 reatment of Advanced Solid Tumors\nEstimated primary completion: 14 July 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT062057
 06
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06096779-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06096779)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A St
 udy Evaluating Atezolizumab\, With or Without Bevacizumab\, in Participant
 s With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirr
 hosis\nEstimated primary completion: 30 July 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06096779
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06096779-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06096779)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Stu
 dy Evaluating Atezolizumab\, With or Without Bevacizumab\, in Participants
  With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrh
 osis\nEstimated primary completion: 30 July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06096779
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07714317-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07714317)
DESCRIPTION:Bevacizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Pha
 se Ib/II Multicenter Randomized Control Study of Peri-operative Treatment 
 With Combination of CTLA-4\, PD-1 Antibodies and Bevacizumab in Resectable
  HCC (Prophet)\nEstimated primary completion: 31 July 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07714317
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04522544-1959@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04522544)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Durval
 umab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage
  HCC\nEstimated primary completion: 31 July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04522544
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07138885-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07138885)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Pha
 se II\, Single-Arm\, Prospective Trial on the Efficacy and Safety of QL170
 6 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Re
 sistant Hepatocellular Carcinoma\nEstimated primary completion: 31 July 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07138885
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04522544-2015@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT04522544)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Durv
 alumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Sta
 ge HCC\nEstimated primary completion: 31 July 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/tremelimumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04522544
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05985798-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT05985798)
DESCRIPTION:Bevacizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: Sinti
 limab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC\nEstimated pri
 mary completion: 31 July 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05985798
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06695026-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT06695026)
DESCRIPTION:Atezolizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: A 
 Study to Evaluate the Safety\, Tolerability and Efficacy of RZ-001 in Comb
 ination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subject
 s With Hepatocellular Carcinoma\nEstimated primary completion: August 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06695026
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06695026-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06695026)
DESCRIPTION:Bevacizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: A S
 tudy to Evaluate the Safety\, Tolerability and Efficacy of RZ-001 in Combi
 nation With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects
  With Hepatocellular Carcinoma\nEstimated primary completion: August 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06695026
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07511504-1959@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07511504)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Y-90 R
 adioembolization\, Durvalumab\, Tremelimumab\, and Zanzalintinib for the T
 reatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma\nEs
 timated primary completion: 1 August 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07511504
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07511504-2015@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT07511504)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Y-90
  Radioembolization\, Durvalumab\, Tremelimumab\, and Zanzalintinib for the
  Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma\n
 Estimated primary completion: 1 August 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tremelimumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07511504
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07100392-1972@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07100392)
DESCRIPTION:Camrelizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Taur
 oursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatoc
 ellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab\n
 Estimated primary completion: 1 August 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07100392
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06679985-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06679985)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Tri
 al of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Par
 ticipants With Unresectable and/or Locally Advanced or Metastatic Hepatoce
 llular Carcinoma\nEstimated primary completion: September 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06679985
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07774247-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07774247)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Atez
 olizumab\, Bevacizumab\, and Tocilizumab in Advanced Hepatocellular Carcin
 oma\nEstimated primary completion: 1 September 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07774247
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07774247-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07774247)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Atezo
 lizumab\, Bevacizumab\, and Tocilizumab in Advanced Hepatocellular Carcino
 ma\nEstimated primary completion: 1 September 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07774247
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05976568-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT05976568)
DESCRIPTION:Bevacizumab\, phase 2/3\, Hepatocellular Carcinoma.\nStudy: A S
 tudy of QL1706 in Combination With Bevacizumab and/or Chemotherapy as Firs
 t-line Treatment in Patients With Advanced Hepatocellular Carcinoma\nEstim
 ated primary completion: 1 September 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05976568
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06045975-1959@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270927
DTEND;VALUE=DATE:20270928
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06045975)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Durval
 umab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC
  Treated by by Percutaneous Ablation Procedure\nEstimated primary completi
 on: 27 September 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06045975
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06045975-2015@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270927
DTEND;VALUE=DATE:20270928
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT06045975)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Durv
 alumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With H
 CC Treated by by Percutaneous Ablation Procedure\nEstimated primary comple
 tion: 27 September 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/tremelimumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06045975
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06526104-1959@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06526104)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Study 
 of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellu
 lar Carcinomas With Child-Pugh-B Cirrhosis\nEstimated primary completion: 
 1 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durva
 lumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06526104
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06526104-2015@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT06526104)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Stud
 y of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocel
 lular Carcinomas With Child-Pugh-B Cirrhosis\nEstimated primary completion
 : 1 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tre
 melimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06526104
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07027436-1959@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271012
DTEND;VALUE=DATE:20271013
SUMMARY:Durvalumab: Phase 3 readout est. (NCT07027436)
DESCRIPTION:Durvalumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: Radiat
 ion Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery
  Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellula
 r Carcinoma.\nEstimated primary completion: 12 October 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07027436
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07027436-2015@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271012
DTEND;VALUE=DATE:20271013
SUMMARY:Tremelimumab: Phase 3 readout est. (NCT07027436)
DESCRIPTION:Tremelimumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: Radi
 ation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surge
 ry Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellu
 lar Carcinoma.\nEstimated primary completion: 12 October 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/tremelimumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07027436
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227012-2009@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271018
DTEND;VALUE=DATE:20271019
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT07227012)
DESCRIPTION:Ipilimumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Symb
 iotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a
  Single Treatment and Combination Treatment in Adult Participants With a L
 iver Cancer Called Hepatocellular Carcinoma\, That is Too Advanced to be R
 emoved by Surgery and May Have Spread to Other Parts of the Body.\nEstimat
 ed primary completion: 18 October 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07227012
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07239245-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271110
DTEND;VALUE=DATE:20271111
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07239245)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Stud
 y to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizuma
 b Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinam
 o\nEstimated primary completion: 10 November 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07239245
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07239245-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271110
DTEND;VALUE=DATE:20271111
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07239245)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Study
  to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab
  Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
 \nEstimated primary completion: 10 November 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07239245
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07522411-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07522411)
DESCRIPTION:Bevacizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Seq
 uential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy V
 ersus Direct Resection in Resectable High-Risk Recurrence Hepatocellular C
 arcinoma\nEstimated primary completion: December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07522411
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07179900-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07179900)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Radio
 therapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastat
 ic Hepatocellular Carcinoma\nEstimated primary completion: December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07179900
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05733598-1959@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05733598)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Study 
 of RP2 in Combination With Second-line Therapy in Patients With Locally Ad
 vanced or Metastatic HCC\nEstimated primary completion: 1 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05733598
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05733598-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05733598)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Stud
 y of RP2 in Combination With Second-line Therapy in Patients With Locally 
 Advanced or Metastatic HCC\nEstimated primary completion: 1 December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05733598
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05733598-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05733598)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Study
  of RP2 in Combination With Second-line Therapy in Patients With Locally A
 dvanced or Metastatic HCC\nEstimated primary completion: 1 December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05733598
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05438420-1973@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05438420)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Cervical Cancer.\nStudy: Oral Axl/M
 er/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pemb
 rolizumab in Patients With Selected Advanced Solid Tumors\nEstimated prima
 ry completion: 30 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05438420
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07380633-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07380633)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Torip
 alimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE\, HA
 IC\, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2\, 
 Multicenter Randomised Non-comparative Trial\nEstimated primary completion
 : 30 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 evacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07380633
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07119931-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07119931)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Cli
 nical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Inj
 ection Plus Bevacizumab in Patients With Initially Potentially Resectable 
 Hepatocellular Carcinoma (ITBHaic Study)\nEstimated primary completion: 30
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevac
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07119931
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07327788-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07327788)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: QL170
 6 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcin
 oma With Vp3/4 PVTT\nEstimated primary completion: 30 December 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07327788
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06362369-1974@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06362369)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed 
 by Nivolumab Monotherapy\nEstimated primary completion: 31 December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06362369
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06362369-2009@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT06362369)
DESCRIPTION:Ipilimumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed
  by Nivolumab Monotherapy\nEstimated primary completion: 31 December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06362369
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04588051-2031@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT04588051)
DESCRIPTION:Cabozantinib\, phase 2\, Hepatocellular Carcinoma.\nStudy: Cabo
 zantinib in Hepatocellular Carcinoma\nEstimated primary completion: 31 Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cabozanti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04588051
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07314372-1972@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07314372)
DESCRIPTION:Camrelizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: FAD 
 Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcino
 ma\nEstimated primary completion: 31 December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07314372
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07314372-2014@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Apatinib: Phase 2 readout est. (NCT07314372)
DESCRIPTION:Apatinib\, phase 2\, Hepatocellular Carcinoma.\nStudy: FAD Subt
 ype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma\n
 Estimated primary completion: 31 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/apatinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07314372
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154082-1972@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07154082)
DESCRIPTION:Camrelizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Apat
 inib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy f
 or Hepatocellular Carcinoma\nEstimated primary completion: 31 December 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/camrelizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07154082
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154082-2014@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Apatinib: Phase 2 readout est. (NCT07154082)
DESCRIPTION:Apatinib\, phase 2\, Hepatocellular Carcinoma.\nStudy: Apatinib
  Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for H
 epatocellular Carcinoma\nEstimated primary completion: 31 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07154082
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06954467-2239@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:JS207: Phase 2 readout est. (NCT06954467)
DESCRIPTION:JS207\, phase 2\, Hepatocellular Carcinoma.\nStudy: JS207 Combi
 ned With JS007 as First-line Treatment for Advanced Hepatocellular Carcino
 ma\nEstimated primary completion: 31 December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/js207#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06954467
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07490262-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT07490262)
DESCRIPTION:Bevacizumab\, phase 2/3\, Hepatocellular Carcinoma.\nStudy: A S
 tudy to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combinat
 ion Therapy in Patients With Hepatocellular Carcinoma as First-line Treatm
 ent.\nEstimated primary completion: 31 December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07490262
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07324473-1972@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07324473)
DESCRIPTION:Camrelizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Ivar
 macitinib Combined With Camrelizumab and Apatinib for Unresectable Advance
 d Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint T
 herapy: A Single-Arm Exploratory Clinical Study\nEstimated primary complet
 ion: 1 January 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 camrelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07324473
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07324473-2014@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Apatinib: Phase 2 readout est. (NCT07324473)
DESCRIPTION:Apatinib\, phase 2\, Hepatocellular Carcinoma.\nStudy: Ivarmaci
 tinib Combined With Camrelizumab and Apatinib for Unresectable Advanced He
 patocellular Carcinoma With Acquired Resistance to Immune Checkpoint Thera
 py: A Single-Arm Exploratory Clinical Study\nEstimated primary completion:
  1 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/apat
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07324473
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06294548-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT06294548)
DESCRIPTION:Atezolizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: A 
 Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizuma
 b in HCC\nEstimated primary completion: 30 January 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06294548
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06294548-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06294548)
DESCRIPTION:Bevacizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: A S
 tudy of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab
  in HCC\nEstimated primary completion: 30 January 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06294548
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07128251-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07128251)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Sin
 gle-Arm\, Multicenter\, Exploratory Clinical Study of Transarterial Chemoe
 mbolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection an
 d Bevacizumab Injection for the Treatment of Unresectable\, Non-Metastatic
  Hepatocellular Carcinoma (HCC)\nEstimated primary completion: 30 January 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0712825
 1
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06880523-1959@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06880523)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: STRIDE
  (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectab
 le Hepatocellular Carcinoma\nEstimated primary completion: 31 January 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06880523
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06880523-2015@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT06880523)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: STRI
 DE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresect
 able Hepatocellular Carcinoma\nEstimated primary completion: 31 January 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/tremelimumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06880523
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04727307-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04727307)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Neoa
 djuvant Atezo\, Adjuvant Atezo + Beva Combined With RF Ablation of Small H
 CC: a Multicenter Randomized Phase II Trial\nEstimated primary completion:
  February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezo
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04727307
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04727307-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT04727307)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Neoad
 juvant Atezo\, Adjuvant Atezo + Beva Combined With RF Ablation of Small HC
 C: a Multicenter Randomized Phase II Trial\nEstimated primary completion: 
 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevaci
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04727307
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226063-1959@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07226063)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Mainte
 nance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocel
 lular Cancer\nEstimated primary completion: February 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07226063
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06796803-1972@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280220
DTEND;VALUE=DATE:20280221
SUMMARY:Camrelizumab: Phase 2/3 readout est. (NCT06796803)
DESCRIPTION:Camrelizumab\, phase 2/3\, Hepatocellular Carcinoma.\nStudy: Ca
 mrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemoth
 erapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellul
 ar Carcinoma(HCC)\nEstimated primary completion: 20 February 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/camrelizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06796803
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06796803-2014@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280220
DTEND;VALUE=DATE:20280221
SUMMARY:Apatinib: Phase 2/3 readout est. (NCT06796803)
DESCRIPTION:Apatinib\, phase 2/3\, Hepatocellular Carcinoma.\nStudy: Camrel
 izumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherap
 y (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular C
 arcinoma(HCC)\nEstimated primary completion: 20 February 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06796803
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04380545-1974@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT04380545)
DESCRIPTION:Nivolumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Nivol
 umab\, Fluorouracil\, and Interferon Alpha 2B for the Treatment of Unresec
 table Fibrolamellar Cancer\nEstimated primary completion: 28 February 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04380545
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07487662-2009@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280319
DTEND;VALUE=DATE:20280320
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07487662)
DESCRIPTION:Ipilimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: TACE o
 r Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Ther
 apy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurre
 nce Risk\nEstimated primary completion: 19 March 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07487662
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05528952-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280327
DTEND;VALUE=DATE:20280328
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05528952)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Eval
 uation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived
  From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatoc
 ellular Carcinoma\nEstimated primary completion: 27 March 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05528952
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05528952-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280327
DTEND;VALUE=DATE:20280328
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05528952)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Evalu
 ation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived 
 From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatoce
 llular Carcinoma\nEstimated primary completion: 27 March 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05528952
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06911255-1959@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT06911255)
DESCRIPTION:Durvalumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Safe
 ty and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable 
 Hepatocellular Carcinoma\nEstimated primary completion: 31 March 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06911255
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05269381-1973@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05269381)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrol
 izumab for Treatment of Advanced Solid Tumors\nEstimated primary completio
 n: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 brolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05269381
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06911255-2015@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Tremelimumab: Phase 1/2 readout est. (NCT06911255)
DESCRIPTION:Tremelimumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Sa
 fety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectabl
 e Hepatocellular Carcinoma\nEstimated primary completion: 31 March 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/tremelimumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06911255
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07911683-2390@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:BGB-B2033: Phase 2 readout est. (NCT07911683)
DESCRIPTION:BGB-B2033\, phase 2\, Hepatocellular Carcinoma.\nStudy: Study E
 valuating the Efficacy and Safety of BGB-B2033 in Participants With Advanc
 ed Hepatocellular Carcinoma\nEstimated primary completion: 31 March 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/bgb-b2033#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07911683
URL:https://assetmemo.bio/drug/bgb-b2033#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07551778-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07551778)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
 llogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in 
 Advanced Solid Tumors\nEstimated primary completion: April 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07551778
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07479485-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07479485)
DESCRIPTION:Bevacizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: MRG
 006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II
 )\nEstimated primary completion: April 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07479485
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07495579-2058@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Regorafenib: Phase 2 readout est. (NCT07495579)
DESCRIPTION:Regorafenib\, phase 2\, Hepatocellular Carcinoma.\nStudy: Lenva
 tinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunothe
 rapy (REVIVE)\nEstimated primary completion: April 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/regorafenib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07495579
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07514429-2058@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Regorafenib: Phase 2 readout est. (NCT07514429)
DESCRIPTION:Regorafenib\, phase 2\, Hepatocellular Carcinoma.\nStudy: Regor
 afenib After Failure of Lenvatinib in Patients With Unresectable HCC: The 
 RELEVANT-HCC Trial\nEstimated primary completion: 31 May 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/regorafenib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07514429
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07514455-2058@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Regorafenib: Phase 2 readout est. (NCT07514455)
DESCRIPTION:Regorafenib\, phase 2\, Hepatocellular Carcinoma.\nStudy: Regor
 afenib After Treatment Failure of First Line Immune Checkpoint Inhibitor T
 reatment in Advanced Hepatocellular Carcinoma Patients\nEstimated primary 
 completion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/regorafenib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07514455
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07151326-2031@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT07151326)
DESCRIPTION:Cabozantinib\, phase 2\, Hepatocellular Carcinoma.\nStudy: Cabo
 zantinib for Progressive HCC Post-first-line Immuno-oncologic Combination 
 Therapy\nEstimated primary completion: June 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07151326
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07282509-1973@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280626
DTEND;VALUE=DATE:20280627
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07282509)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: S
 afety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With 
 Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer\nEstim
 ated primary completion: 26 June 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07282509
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03539822-1959@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT03539822)
DESCRIPTION:Durvalumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Cabo
 zantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gas
 troesophageal Cancer and Other Gastrointestinal Malignancies\nEstimated pr
 imary completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT03539822
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03539822-2015@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Tremelimumab: Phase 1/2 readout est. (NCT03539822)
DESCRIPTION:Tremelimumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Ca
 bozantinib Plus Durvalumab With or Without Tremelimumab in Patients With G
 astroesophageal Cancer and Other Gastrointestinal Malignancies\nEstimated 
 primary completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/tremelimumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT03539822
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03539822-2031@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Cabozantinib: Phase 1/2 readout est. (NCT03539822)
DESCRIPTION:Cabozantinib\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Ca
 bozantinib Plus Durvalumab With or Without Tremelimumab in Patients With G
 astroesophageal Cancer and Other Gastrointestinal Malignancies\nEstimated 
 primary completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/cabozantinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT03539822
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06737913-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06737913)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: HAI o
 r IV of Adebrelimab\, Combined With Bevacizumab and HAI of FOLFOX for Adva
 nced Unresectable Hepatocellular Carcinoma\nEstimated primary completion: 
 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevaciz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06737913
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07749859-2014@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Apatinib: Phase 2 readout est. (NCT07749859)
DESCRIPTION:Apatinib\, phase 2\, Hepatocellular Carcinoma.\nStudy: SHR-1701
  Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Adv
 anced Hepatocellular Carcinoma\nEstimated primary completion: July 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07749859
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07062055-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280725
DTEND;VALUE=DATE:20280726
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07062055)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: BITS-
 TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT f
 or BCLC-C HCC With PVTT and/or Oligometastases\nEstimated primary completi
 on: 25 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bev
 acizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07062055
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04430452-1959@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04430452)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Durval
 umab With/Without Tremelimumab After Palliative Hypofractionated Radiother
 apy for Hepatocellular Carcinoma\nEstimated primary completion: 31 July 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04430452
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04430452-2015@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT04430452)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Durv
 alumab With/Without Tremelimumab After Palliative Hypofractionated Radioth
 erapy for Hepatocellular Carcinoma\nEstimated primary completion: 31 July 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/tremelimumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT044304
 52
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06172205-1972@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Camrelizumab: Phase 3 readout est. (NCT06172205)
DESCRIPTION:Camrelizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: Infu
 sional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizu
 mab and Apatinib for Advanced HCC\nEstimated primary completion: 31 July 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/camrelizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0617220
 5
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06172205-2014@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Apatinib: Phase 3 readout est. (NCT06172205)
DESCRIPTION:Apatinib\, phase 3\, Hepatocellular Carcinoma.\nStudy: Infusion
 al FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab 
 and Apatinib for Advanced HCC\nEstimated primary completion: 31 July 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06172205
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05317819-2830@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Pegargiminase: Phase 3 readout est. (NCT05317819)
DESCRIPTION:Pegargiminase\, phase 3\, Hepatocellular Carcinoma.\nStudy: Stu
 dy of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and U
 nresectable Hepatocellular Carcinoma\nEstimated primary completion: Septem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pegargimina
 se#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5317819
URL:https://assetmemo.bio/drug/pegargiminase#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06027086-1959@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT06027086)
DESCRIPTION:Durvalumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: DRP-
 104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With
  Advanced Stage Fibrolamellar Carcinoma (FLC)\nEstimated primary completio
 n: 1 September 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06027086
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06133062-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06133062)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Atez
 olizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatoc
 ellular Carcinoma\nEstimated primary completion: 30 September 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06133062
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06133062-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06133062)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Atezo
 lizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatoce
 llular Carcinoma\nEstimated primary completion: 30 September 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06133062
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06789757-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20281027
DTEND;VALUE=DATE:20281028
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06789757)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: The 
 Study of Atezolizumab\, Bevacizumab and Memantine in Patients With Hepatoc
 ellular Carcinoma (HCC)\nEstimated primary completion: 27 October 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06789757
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06789757-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20281027
DTEND;VALUE=DATE:20281028
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06789757)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: The S
 tudy of Atezolizumab\, Bevacizumab and Memantine in Patients With Hepatoce
 llular Carcinoma (HCC)\nEstimated primary completion: 27 October 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06789757
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06680258-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT06680258)
DESCRIPTION:Atezolizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: A St
 udy of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unres
 ectable or Metastatic HCC Not Previously Treated With Systemic Therapy\nEs
 timated primary completion: December 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06680258
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06680258-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT06680258)
DESCRIPTION:Bevacizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: A Stu
 dy of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unrese
 ctable or Metastatic HCC Not Previously Treated With Systemic Therapy\nEst
 imated primary completion: December 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06680258
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06680258-2171@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Amezalpat: Phase 3 readout est. (NCT06680258)
DESCRIPTION:Amezalpat\, phase 3\, Hepatocellular Carcinoma.\nStudy: A Study
  of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresect
 able or Metastatic HCC Not Previously Treated With Systemic Therapy\nEstim
 ated primary completion: December 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/amezalpat#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06680258
URL:https://assetmemo.bio/drug/amezalpat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07331883-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07331883)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Sinti
 limab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Res
 ection of Ruptured Hepatocellular Carcinoma (CLEAR-2)\nEstimated primary c
 ompletion: 1 December 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07331883
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07317414-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20281205
DTEND;VALUE=DATE:20281206
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07317414)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: β-a
 lanine in the Treatment of Advanced Hepatocellular Carcinoma\nEstimated pr
 imary completion: 5 December 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07317414
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07317414-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20281205
DTEND;VALUE=DATE:20281206
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07317414)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: β-al
 anine in the Treatment of Advanced Hepatocellular Carcinoma\nEstimated pri
 mary completion: 5 December 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07317414
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492408-1959@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06492408)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Neoadj
 uvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.\nEsti
 mated primary completion: 30 December 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06492408
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492408-1973@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06492408)
DESCRIPTION:Pembrolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Neo
 adjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.\nE
 stimated primary completion: 30 December 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06492408
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492408-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06492408)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Neoad
 juvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.\nEst
 imated primary completion: 30 December 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06492408
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492408-2009@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT06492408)
DESCRIPTION:Ipilimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Neoadj
 uvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.\nEsti
 mated primary completion: 30 December 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06492408
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04988945-1959@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04988945)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: TACE a
 nd SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Ca
 rcinoma\nEstimated primary completion: 31 December 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT04988945
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04988945-2015@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT04988945)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: TACE
  and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular 
 Carcinoma\nEstimated primary completion: 31 December 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/tremelimumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04988945
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05441475-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05441475)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Pha
 se 2\, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Pa
 tients\nEstimated primary completion: 31 December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05441475
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07324824-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07324824)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Sinti
 limab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable He
 patocellular Carcinoma\nEstimated primary completion: January 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07324824
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07328009-1972@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20290115
DTEND;VALUE=DATE:20290116
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07328009)
DESCRIPTION:Camrelizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Pl
 atform Trial for Personalized and Adaptive Therapies in Hepatocellular Car
 cinoma\nEstimated primary completion: 15 January 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07328009
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04712643-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT04712643)
DESCRIPTION:Atezolizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: A St
 udy of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in P
 atients With Untreated Heaptocellular Carcionma\nEstimated primary complet
 ion: 1 February 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04712643
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04712643-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT04712643)
DESCRIPTION:Bevacizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: A Stu
 dy of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Pa
 tients With Untreated Heaptocellular Carcionma\nEstimated primary completi
 on: 1 February 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT04712643
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06339424-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20290330
DTEND;VALUE=DATE:20290331
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06339424)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Atez
 olizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatoc
 ellular Carcinoma\nEstimated primary completion: 30 March 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06339424
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06339424-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20290330
DTEND;VALUE=DATE:20290331
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06339424)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Atezo
 lizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatoce
 llular Carcinoma\nEstimated primary completion: 30 March 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06339424
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07010497-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07010497)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Pr
 ospective Study to Evaluate the Safety and Efficacy of the Combination The
 rapy of Irpagratinib\, Atezolizumab\, and Bevacizumab in Patients With Hep
 atocellular Carcinoma\nEstimated primary completion: 31 March 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07010497
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07010497-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07010497)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Pro
 spective Study to Evaluate the Safety and Efficacy of the Combination Ther
 apy of Irpagratinib\, Atezolizumab\, and Bevacizumab in Patients With Hepa
 tocellular Carcinoma\nEstimated primary completion: 31 March 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07010497
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06789848-1994@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT06789848)
DESCRIPTION:Cadonilimab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Liguf
 alimab and Cadonilimab in Advanced Liver Cancers\nEstimated primary comple
 tion: 31 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ca
 donilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06789848
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07461675-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT07461675)
DESCRIPTION:Atezolizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: Effe
 cts of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular
  Carcinoma Patients Undergoing Liver Resection\nEstimated primary completi
 on: 1 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atez
 olizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07461675
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06605664-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06605664)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Hype
 rpolarized 13C-MRI in Patients With Hepatocellular Carcinoma Undergoing Ra
 diotherapy\, Atezolizumab\, and Bevacizumab\nEstimated primary completion:
  30 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezol
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06605664
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06605664-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06605664)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Hyper
 polarized 13C-MRI in Patients With Hepatocellular Carcinoma Undergoing Rad
 iotherapy\, Atezolizumab\, and Bevacizumab\nEstimated primary completion: 
 30 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevaciz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06605664
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1959@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Durvalumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: QUIL
 T-3.055: A Study of Combination Immunotherapies in Patients Who Have Previ
 ously Received Treatment With Immune Checkpoint Inhibitors\nEstimated prim
 ary completion: 31 August 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: QU
 ILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Pre
 viously Received Treatment With Immune Checkpoint Inhibitors\nEstimated pr
 imary completion: 31 August 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1973@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Q
 UILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Pr
 eviously Received Treatment With Immune Checkpoint Inhibitors\nEstimated p
 rimary completion: 31 August 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1974@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: QUILT
 -3.055: A Study of Combination Immunotherapies in Patients Who Have Previo
 usly Received Treatment With Immune Checkpoint Inhibitors\nEstimated prima
 ry completion: 31 August 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07543783-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07543783)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Effic
 acy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Tran
 sarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemothe
 rapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular C
 arcinoma: A Single-arm Phase 2 Trial\nEstimated primary completion: 31 Aug
 ust 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075
 43783
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219459-1974@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07219459)
DESCRIPTION:Nivolumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Visugro
 mab\, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib i
 n Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Fa
 ilure\nEstimated primary completion: September 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07219459
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06904170-1959@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20290914
DTEND;VALUE=DATE:20290915
SUMMARY:Durvalumab: Phase 2/3 readout est. (NCT06904170)
DESCRIPTION:Durvalumab\, phase 2/3\, Hepatocellular Carcinoma.\nStudy: Durv
 alumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemo
 therapy in Hepatocellular Carcinoma\nEstimated primary completion: 14 Sept
 ember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvaluma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 904170
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06904170-2015@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20290914
DTEND;VALUE=DATE:20290915
SUMMARY:Tremelimumab: Phase 2/3 readout est. (NCT06904170)
DESCRIPTION:Tremelimumab\, phase 2/3\, Hepatocellular Carcinoma.\nStudy: Du
 rvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Che
 motherapy in Hepatocellular Carcinoma\nEstimated primary completion: 14 Se
 ptember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tremeli
 mumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06904170
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07836530-2390@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20290921
DTEND;VALUE=DATE:20290922
SUMMARY:BGB-B2033: Phase 3 readout est. (NCT07836530)
DESCRIPTION:BGB-B2033\, phase 3\, Hepatocellular Carcinoma.\nStudy: Study C
 omparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular
  Carcinoma\nEstimated primary completion: 21 September 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/bgb-b2033#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07836530
URL:https://assetmemo.bio/drug/bgb-b2033#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07761286-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07761286)
DESCRIPTION:Bevacizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Eva
 luate the Safety and Efficacy of Combination Therapy With SYS6090 Injectio
 n for Hepatocellular Carcinoma\nEstimated primary completion: 30 September
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077612
 86
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07847671-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07847671)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Fecal
  Microbiota Transplantation Combined With QL1706 Plus Bevacizumab for Adva
 nced HCC\nEstimated primary completion: October 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07847671
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07835737-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT07835737)
DESCRIPTION:Atezolizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Sa
 fety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab
  as First-Line Therapy for Unresectable Hepatocellular Carcinoma\nEstimate
 d primary completion: 1 October 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07835737
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07835737-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07835737)
DESCRIPTION:Bevacizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Saf
 ety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab 
 as First-Line Therapy for Unresectable Hepatocellular Carcinoma\nEstimated
  primary completion: 1 October 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07835737
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07291076-2009@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20291015
DTEND;VALUE=DATE:20291016
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT07291076)
DESCRIPTION:Ipilimumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: A St
 udy to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combi
 nation With Ipilimumab in Participants With First-Line Advanced or Unresec
 table Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)\nEstimated primary 
 completion: 15 October 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07291076
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07823348-2239@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20291030
DTEND;VALUE=DATE:20291031
SUMMARY:JS207: Phase 3 readout est. (NCT07823348)
DESCRIPTION:JS207\, phase 3\, Hepatocellular Carcinoma.\nStudy: JS207 Plus 
 JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Adva
 nced Liver Cancer\nEstimated primary completion: 30 October 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/js207#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07823348
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06254248-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06254248)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Safe
 ty of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advance
 d Hepatocellular Carcinoma\nEstimated primary completion: 1 January 2030. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06254248
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06254248-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06254248)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Safet
 y of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced
  Hepatocellular Carcinoma\nEstimated primary completion: 1 January 2030. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06254248
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07122089-1959@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20300102
DTEND;VALUE=DATE:20300103
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07122089)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Evalua
 tion of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Car
 cinoma With Portal Vein Thrombosis\nEstimated primary completion: 2 Januar
 y 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071220
 89
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07122089-2015@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20300102
DTEND;VALUE=DATE:20300103
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT07122089)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Eval
 uation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular C
 arcinoma With Portal Vein Thrombosis\nEstimated primary completion: 2 Janu
 ary 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tremelimuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 122089
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392866-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20300301
DTEND;VALUE=DATE:20300302
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT07392866)
DESCRIPTION:Bevacizumab\, phase 2/3\, Hepatocellular Carcinoma.\nStudy: A C
 linical Study of SH006 Injection in Combination Therapy Versus Regorafenib
  in the Treatment of Advanced Hepatocellular Carcinoma\nEstimated primary 
 completion: 1 March 2030. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07392866
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06921785-1986@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20300315
DTEND;VALUE=DATE:20300316
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT06921785)
DESCRIPTION:Rilvegostomig\, phase 3\, Hepatocellular Carcinoma.\nStudy: Pha
 se III Study of Rilvegostomig in Combination With Bevacizumab With or With
 out Tremelimumab as First-line Treatment of Hepatocellular Carcinoma\nEsti
 mated primary completion: 15 March 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/rilvegostomig#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06921785
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06921785-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20300315
DTEND;VALUE=DATE:20300316
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT06921785)
DESCRIPTION:Bevacizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: Phase
  III Study of Rilvegostomig in Combination With Bevacizumab With or Withou
 t Tremelimumab as First-line Treatment of Hepatocellular Carcinoma\nEstima
 ted primary completion: 15 March 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06921785
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06921785-2015@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20300315
DTEND;VALUE=DATE:20300316
SUMMARY:Tremelimumab: Phase 3 readout est. (NCT06921785)
DESCRIPTION:Tremelimumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: Phas
 e III Study of Rilvegostomig in Combination With Bevacizumab With or Witho
 ut Tremelimumab as First-line Treatment of Hepatocellular Carcinoma\nEstim
 ated primary completion: 15 March 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tremelimumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06921785
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594340-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20300530
DTEND;VALUE=DATE:20300531
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07594340)
DESCRIPTION:Bevacizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: HAIC 
 vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Be
 yond Up-To-Seven)\nEstimated primary completion: 30 May 2030. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07594340
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06999694-1959@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06999694)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Proton
  Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC\nEst
 imated primary completion: 31 May 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06999694
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06999707-1959@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06999707)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Photon
  Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC\nEst
 imated primary completion: 31 May 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06999707
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06999694-2015@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT06999694)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Prot
 on Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC\nE
 stimated primary completion: 31 May 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tremelimumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06999694
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06999707-2015@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT06999707)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Phot
 on Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC\nE
 stimated primary completion: 31 May 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tremelimumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06999707
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07620574-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT07620574)
DESCRIPTION:Atezolizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: Long
 -Term Extension Study for Participants Previously Enrolled in an Exelixis-
 Sponsored Study\nEstimated primary completion: 31 May 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07620574
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07620574-1974@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Nivolumab: Phase 3 readout est. (NCT07620574)
DESCRIPTION:Nivolumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: Long-Te
 rm Extension Study for Participants Previously Enrolled in an Exelixis-Spo
 nsored Study\nEstimated primary completion: 31 May 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07620574
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07620574-2031@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Cabozantinib: Phase 3 readout est. (NCT07620574)
DESCRIPTION:Cabozantinib\, phase 3\, Hepatocellular Carcinoma.\nStudy: Long
 -Term Extension Study for Participants Previously Enrolled in an Exelixis-
 Sponsored Study\nEstimated primary completion: 31 May 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07620574
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06726161-11185@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:RYZ801: Phase 1/2 readout est. (NCT06726161)
DESCRIPTION:RYZ801\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Study of
  the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Iden
 tify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC\nEstimate
 d primary completion: June 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ryz801#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06726161
URL:https://assetmemo.bio/drug/ryz801#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07882056-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07882056)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: SBRT 
 Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for He
 patocellular Carcinoma\nEstimated primary completion: August 2030. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07882056
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03942328-1959@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT03942328)
DESCRIPTION:Durvalumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Modi
 fied Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Com
 bined With Immune Checkpoint Inhibition After High-Dose External Beam Radi
 ation Therapy in Treating Patients With Unresectable Liver Cancer\nEstimat
 ed primary completion: 31 August 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT03942328
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03942328-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT03942328)
DESCRIPTION:Atezolizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Mo
 dified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) C
 ombined With Immune Checkpoint Inhibition After High-Dose External Beam Ra
 diation Therapy in Treating Patients With Unresectable Liver Cancer\nEstim
 ated primary completion: 31 August 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT03942328
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03942328-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT03942328)
DESCRIPTION:Bevacizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Mod
 ified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Co
 mbined With Immune Checkpoint Inhibition After High-Dose External Beam Rad
 iation Therapy in Treating Patients With Unresectable Liver Cancer\nEstima
 ted primary completion: 31 August 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT03942328
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223424-1973@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07223424)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: P
 atient Preference for Subcutaneous vs. Intravenous Immune Therapy\nEstimat
 ed primary completion: 30 November 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07223424
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223424-1974@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07223424)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Patie
 nt Preference for Subcutaneous vs. Intravenous Immune Therapy\nEstimated p
 rimary completion: 30 November 2030. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07223424
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06739317-1972@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Camrelizumab: Phase 2/3 readout est. (NCT06739317)
DESCRIPTION:Camrelizumab\, phase 2/3\, Hepatocellular Carcinoma.\nStudy: SB
 RT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patie
 nts with Unresectable Hepatocellular Carcinoma.\nEstimated primary complet
 ion: 31 December 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/camrelizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06739317
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06739317-2014@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Apatinib: Phase 2/3 readout est. (NCT06739317)
DESCRIPTION:Apatinib\, phase 2/3\, Hepatocellular Carcinoma.\nStudy: SBRT C
 ombined with Camrelizumab and Apatinib for Conversion Therapy in Patients 
 with Unresectable Hepatocellular Carcinoma.\nEstimated primary completion:
  31 December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ap
 atinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06739317
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06725121-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT06725121)
DESCRIPTION:Atezolizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Us
 ing Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before T
 ransplant\nEstimated primary completion: June 2031. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06725121
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06725121-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06725121)
DESCRIPTION:Bevacizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Usi
 ng Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Tr
 ansplant\nEstimated primary completion: June 2031. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06725121
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018947-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07018947)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Stud
 y to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as N
 eoadjuvant Plus Adjuvant Treatment in HCC\nEstimated primary completion: J
 une 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 018947
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018947-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07018947)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Study
  to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Ne
 oadjuvant Plus Adjuvant Treatment in HCC\nEstimated primary completion: Ju
 ne 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0701
 8947
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07691762-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07691762)
DESCRIPTION:Bevacizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: A Stu
 dy of TACE in Combination With SHR-8068\, Adebrelimab\, and Bevacizumab Ve
 rsus TACE in Participants With Incurable Hepatocellular Carcinoma\nEstimat
 ed primary completion: September 2031. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07691762
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07813572-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07813572)
DESCRIPTION:Bevacizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: ZG005
  Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for
  Advanced Hepatocellular\nEstimated primary completion: September 2031. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07813572
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07813572-2822@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Nilvanstomig: Phase 3 readout est. (NCT07813572)
DESCRIPTION:Nilvanstomig\, phase 3\, Hepatocellular Carcinoma.\nStudy: ZG00
 5 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy fo
 r Advanced Hepatocellular\nEstimated primary completion: September 2031. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/nilvanstomig#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07813572
URL:https://assetmemo.bio/drug/nilvanstomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07689175-1974@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07689175)
DESCRIPTION:Nivolumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Adaptiv
 e Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma\nEst
 imated primary completion: 31 October 2031. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07689175
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07689175-2009@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07689175)
DESCRIPTION:Ipilimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Adapti
 ve Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma\nEs
 timated primary completion: 31 October 2031. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07689175
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04114136-1973@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20320430
DTEND;VALUE=DATE:20320501
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04114136)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
 nti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies\nEstimat
 ed primary completion: 30 April 2032. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04114136
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04114136-1974@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20320430
DTEND;VALUE=DATE:20320501
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04114136)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Anti-
 PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies\nEstimated p
 rimary completion: 30 April 2032. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04114136
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05468359-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT05468359)
DESCRIPTION:Atezolizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Sa
 fety and Efficacy of Cyclophosphamide\, Sorafenib\, Bevacizumab\, and Atez
 olizumab in Pediatric Solid Tumor Patients\nEstimated primary completion: 
 June 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5468359
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05468359-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT05468359)
DESCRIPTION:Bevacizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Saf
 ety and Efficacy of Cyclophosphamide\, Sorafenib\, Bevacizumab\, and Atezo
 lizumab in Pediatric Solid Tumor Patients\nEstimated primary completion: J
 une 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT054
 68359
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05620771-1962@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20400701
DTEND;VALUE=DATE:20400702
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05620771)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Ther
 asphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma 
 That is High-risk\nEstimated primary completion: 1 July 2040. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05620771
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05620771-2008@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20400701
DTEND;VALUE=DATE:20400702
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05620771)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Thera
 sphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma T
 hat is High-risk\nEstimated primary completion: 1 July 2040. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05620771
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
